Alternative splicing and its contribution to cognitive decline in the ageing brain by Lye, J
Alternative splicing and age-related neurodegeneration – Jed Lye 
Page 1 of 86 
 
Alternative splicing and its 




Submitted by Jed Lye to the University of Exeter as a thesis for the degree of Master’s by Research 
in Medical Sciences 
September 2019 
 
This thesis is available for library use on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement. 
 
I certify that all material which is not my own work has been identified and that no material has 
previously been submitted and approved for the award of a degree by this or any other university. 
 
Signature          
  
Alternative splicing and age-related neurodegeneration – Jed Lye 




Premature cognitive decline is a feature of age-related pathological processes, often associated with 
neurodegenerative disorders. Part of the systemic ageing process is the accumulation of senescent 
cells in tissues around the body, including the brain. Cellular senescence contributes to the systemic 
inflammation which comes with ageing and disrupts several cellular regulatory mechanisms. 
Alternative splicing is one of these processes. Here, we first characterise the inflammatory component 
or senescence associated secretory phenotype and the splicing dysregulation within astrocytes. We 
then observe and quantify the effects of this on the alternative splicing of essential transcripts related 
to astrocyte function. Finally, we assess the correlation between observable levels of splicing 
perturbation in peripheral whole blood and the progression of cognitive decline in a population study. 
As a result, we identify potential biomarkers for the cognitive decline associated with dementia and 
other neurodegenerative disorders.  
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1 INTRODUCTION 
1.1.1 The burden of age-related neurodegeneration 
 
Age is a major risk factor for cognitive decline and neurodegenerative disease, as it is for most 
common, chronic disorders (1). The process of biological ageing can be generalised as a gradual 
accumulation of molecular and cellular damage in an organism over time (2). The process is positively 
correlated with increased risk of chronic disease, and is the main risk factor for most common 
pathologies in the western world (3). Neurological ageing and associated neurodegenerative disorders 
(NDDs) characterise a group of disorders that have amongst the largest impact on health and quality 
of life for patients and their families; in 2015, 46.8 million people were living with dementia (4-6). 
These disorders also have profound economic consequences; the basic economic costs of dementia-
related illnesses worldwide was estimated as 604 billion dollars in 2010 (7), with 70% of this cost 
focused in Western Europe and North America (4, 6). Dementia survival estimates vary from 1-8.5 
years, depending on the age of onset; those being diagnosed earlier usually having increased survival 
time (8). Disorders characterised by cognitive decline include Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis 
(MS)(9). Whilst specific disease processes may differ, generally the disorders disrupt motor, cognitive 
and sensory function, resulting in inability to perform physical and mental tasks, memory and 
emotional disturbance, and eventually death (9).  
The pathology of NDDs is linked to loss or dysfunction of neurons, which progressively lose ability to 
react to stimuli and eventually degenerate (10). Inflammatory processes are linked to the pathology 
of these disorders (11). Protein aggregates such as -amyloid or α-synuclein, along with neurofibrillary 
tangles consisting of Tau protein, present in brains affected by NDD’s, have been reported to elicit 
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immune responses and potentially contribute to this inflammatory process (12).  Ageing (3), infection 
(13) and trauma (14) have also been correlated to the process of neurodegeneration and associated 
pathologies.  
Recent evidence suggests that the accumulation of senescent cells in the brain may actively drive 
functional decline in NDDs (15). The accumulation of senescent cells in tissues and organs has emerged 
as a major driver of the ageing process and age-related disease in mammals; selective removal of such 
cells in genetically-engineered animals has been demonstrated to reverse or delay aspects of ageing 
(16, 17). Senescence is a phenomenon whereby cells lose the ability to proliferate, and demonstrate 
functional decline and morphological differences to their non-senescent counterparts (18). Senescent 
cells are alive and metabolically active but have altered function compared to their non-senescent 
counterparts. 
 Although neurons are terminally differentiated and therefore non-proliferative, they are supported 
by replication competent cells such microglia and astrocytes. It is likely that senescence-related 
changes to the function of these cells may compromise their roles in metabolic and neuronal ion 
homeostasis (19) (20). Astrocytes have a pivotal role in maintenance of trophic factors, 
neurotransmitters, and the support and strengthening of neuronal connections (21). Previous 
evidence has suggested that the accumulation of senescent astrocytes may drive neurodegenerative 
disorders (22) and recent work shows that clearance of senescent glial cells may prevent the 
accumulation of Tau aggregates and improve cognitive function in mouse models (15, 23). 
Pharmacological impairment of astrocytic function recapitulates cognitive deficits that are observed 
in old age (24). It is also noteworthy that irradiation-induced accumulation of senescent cells is 
associated with cerebro-microvascular dysfunction in animal models (25).    
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 A major feature of senescence is secretion of the senescence associated secretory phenotype (SASP), 
a cocktail of inflammatory cytokines which can act in a paracrine manner on neighbouring cells driving 
them into senescence or growth arrest. This catalyses a vicious cycle of senescence and inflammation 
in surrounding tissues and eventually throughout the entire organism, characterised in ageing (26) 
(27).This hypothesis is supported by the observation that senescent support cells exhibit a reduced 
capacity to support neurons grown in co-culture (28) and that analysis of the brains of patients with 
Alzheimer’s associated dementia, demonstrate a significantly higher load of senescent cells and 
associated SASP factors (29).   
Cells enter a senescent state for a number of reasons, one of which is repeated exposure to internal 
and external stressors (30). Exposure to cellular stress elicits an adaptive and plastic transcriptional 
response, which is partly orchestrated by alternative splicing (31). A large-scale gene enrichment study 
showed that successful or unsuccessful ageing (the primary risk factor for most high mortality 
pathologies), was most closely linked to perturbations in those genes which were linked to mRNA 
processing and splicing (32). 
Supporting the notion of a pivotal role for dysregulated alternative splicing in senescence, transcripts 
associated with chronological age in humans are enriched in gene ontology pathways involved in splice 
site choice (32) and splicing factor expression is also associated with cellular senescence in in-vitro 
models  (33, 34), with human ageing phenotypes (35) and with lifespan in long-lived mice (36). Perhaps 
most persuasively, restoration of splicing factor levels is associated with rescue of cellular senescence 
in multiple human primary human cell types (37-39). 
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Changes to the regulation of splicing have previously been reported in Alzheimer’s Disease (40) and 
global dysregulation of splicing is characteristic of several neurodegenerative conditions such as 
Huntington’s disease (41), frontotemporal lobar dementia (42) and Parkinson’s Disease (43). Specially, 
alterations to the splicing pattern of the MAPT gene which encodes Tau protein is known to contribute 
to neurofibrillary tangles (44). Genes may be regulated at multiple levels, but recent studies have 
demonstrated the importance of mRNA processing in ageing and age-related disease (32, 45). Three 
types of mechanism primarily explain ageing related phenotypes: isoform based loss of function, 
aberrant gain of function and ratio imbalance (46). 
 
1.2 ALTERNATIVE SPLICING 
The stunning complexity of the gene regulatory mechanisms exhibited in human cells is being 
demystified at an ever-increasing rate thanks to rapidly developing technology, increased manpower 
and funding in the bioscience field (47). The central dogma script of molecular biology is being 
continually punctuated with newly-elucidated molecular control mechanisms and regulatory 
processes (48, 49), which add still more layers to the regulation of mRNA transcription, splicing, decay 
and translation, ultimately determining the flux in concentrations of various isoforms of mRNA 
transcripts which direct the molecular production of proteins (50). Over 95% of human genes are able 
to produce different isoforms through these  this contributes in a pivotal way to the complexity of 
higher eukaryotes (51) (52).  
Normal, constitutive splicing is the process of removing intronic sequences from pre-mRNA transcripts 
and binding together the resulting exon sequences to yield a functional, mature mRNA (53). This is 
achieved through number of co-transcriptional or post-transcriptional processes, of which pre-mRNA 
splicing is the most complicated (53).  
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 Splicing occurs through a two-step, transesterification process occurring inside of a multi-megadalton 
ribonucleoprotein complex termed; the spliceosome. The spliceosome is the molecular machine 
through which much of the cellular splicing is done (54).  It consists of 5 small nuclear 
ribonucleoproteins (U1, U2, U4, U5 and U6) in addition to an impressive 150 associated proteins (55). 
A further central core of Sm proteins is needed for the assembly of the spliceosome, and methylation 
patterns of these directly affect their interactions and thus splicing (56). Assembly of the spliceosome 
is initiated first by the recognition of consensus sequences (most commonly GT/AG) at either end of 
the intron (57). U1 binds to the 5’ splice site, two U2 subunits bind to the polypyrimidine tract (plays 
an important role in 3’ splice site selection) and the 3’ AG (58).  
The mRNA transcripts are cleaved at the 5’ splice site with the addition of a hydroxyl group to the 
splice site. The 5’ end is then looped back around and ligated to the 3’ branch site via a 
transesterification process, and the hydroxyl group is excised with the branched lariat loop (54) (see 
Figure 1.1).
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Figure 1.1 Constitutive and regulatory control of splicing processes (personal Communication - L.W.Harries) 
1. Phosphorylated SR and hnRNP proteins bind to their respective intron/exon splicing enhancers and intron/exon splicing suppressors. 2. The U1 and U2 small 
nuclear ribonucleoproteins (snRNPs) bind to the 5’ splice site (SD) and the branch point (BP) respectively. The tri-snRNP consisting of U4, U5 and U6 snRNPs then 
assembles. 3. A lariat loop is formed, by conformational change. And the U1 and the U4 snRNPs are displaced.  4. The intron is removed in the form of a lariat and 5. 
The exons are bound together by a transesterification reaction. SD = Splice donor site. SA = splice acceptor site. BP = branch point. SR = Serine Arginine rich splicing 
activator. HNRNP – Heterogeneous nuclear ribonucleoprotein particle splicing silencer. Exon/Intron Splicing Enhancer sites (ESE, ISE) are indicated by yellow boxes. 
Exon/Intron splicing silencer (ISS, ESS) binding sites are indicated by pale green boxes. 
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In addition, to this canonical molecular process, alternative splicing is the process of producing 
variations of these isoforms from a single pre-mRNA by including or removing exons from transcripts 
in a specific pattern (54).  Alternative splicing is mediated by the combinatorial binding of a series of 
splicing activators and inhibitors to splicing enhancer and silencer sequences around the splice sites 
to determine whether or not each splice site is used (59, 60).In some instances exons are included 
which are normally excluded, in others an exon normally expressed can be spliced out for a mutually 
exclusive alternative (61). 4 basic alternative splicing patterns exist: Alternative 5’ splice site selection, 
alternative 3’ splice-site selection, cassette exon inclusion/ skipping, and intron retention (61). 
Mutually-exclusive alternative exons add an additional layer of complexity to these patterns (62) (See 
Fig 2). The resultant protein isoforms can have differential effects that range from mildly altered 
affinities, to demonstrating complete antagonism (63, 64).   
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Figure 1.2- graphical representation of the patterns of alternative splicing.  
Visual representation of the processes of splicing. Boxes represent exons joined by straight 
black lines representing the introns. Angular lines represent alternative splicing patterns and 
span the nucleic acid content to be removed.  Examples refer to: A) exon skipping, B) intron 
retention, C) alternative 5’ splice site, D) alternative 3’ splice site, E) mutually exclusive exons, 
and alternative F) first and g) last exons. 
 
Through this methodology, the genomic information present in a cell is able to generate an increased 
number of mRNA output variations and contribute to the increased tissue specific and temporal 
plasticity, facilitating adaptation to environmental pressures (65). The degree of transcriptional 
plasticity which can be achieved by this process is only now being fully unravelled.  Computational 
genomic analysis of binding sites for splice factors revealed over 38,000 possible splice variants of a 
single gene (Dscam) in Drosophila melanogaster (66). Whilst this number isn’t representative of the 
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vast majority of alleles, it goes some of the way to illustrating the vastness of the variation which exists 
beyond our basic genetic sequences.  The resultant transcripts can have differential or antagonistic 
function, or in some cases splicing can produce non-viable transcripts by the introduction of 
premature termination codons and thus induction of the nonsense mediated decay (NMD) pathway 
(67).  
The concentrations of, post-translational modifications to, and steric competition which occurs 
between trans-acting factors for cis-regulatory sequences for is a major driver of alternative splicing. 
Splice site usage (or not), is determined by the combinational balance of splicing inhibitors and 
activators (60). Splicing factors shuttle between nucleus and cytoplasm under the control of splicing 
regulator kinases that include Serine Threonine Protein Kinases 1 and 2  (SRPK1 and SRPK2) (68).  
Splicing factors are also themselves regulated by alternative splicing (67).  
As transcription is controlled by the interaction between sequences in the DNA and proteins which 
bind to elicit initiation of transcription, so alternative splicing occurs when splicing regulatory activator 
or silencer proteins bind to exon or intron splicing enhancers (ESEs, ISEs) or silencers (ESS, ISS) in the 
pre-mRNA transcript (69).  Sequence elements acting as enhancers or silencers are termed cis-
regulatory sequencers, whilst those factors which bind to them are termed trans-acting factors (54). 
The relatively low affinity between splicing factors and mRNA is sometimes overcome by duplication 
of cis elements (70) . Splicing inhibitor proteins such as hnRNPs bind to exon splicing silencers, creating 
a loop out between the ESS bound molecule and the 5’ splice site, thereby preventing the binding of 
SR proteins, and sequestering the exon from the pre-mRNA transcript (71). SR proteins, through their 
binding to enhancer elements bring about and stabilise a branch site (71). SR-like proteins are similar 
splicing effector proteins. They are not mandatory for the process of splicing, but have domains which 
are akin to those in SR proteins, enabling them to bind to splice sites in and can work antagonistically 
to the SR proteins (72). Some of these splicing factors which regulate splicing, are also regulated by 
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alternative splicing themselves (67), and a number are auto-regulated, whereby products bind to and 
control the splicing of their own transcripts, whilst also possessing the ability to bind to other 
transcripts with the same conserved sequence (73). 
This network is then further complicated by the role which transcriptional control plays in initiation of 
the process, being as it is; co-transcriptional, as evidenced by chromatin immunoprecipitation (ChIP) 
and RNA polymerase knockout models (74) (75).  Additional mechanism of alternative splicing control 
has been proposed based on results indicating endonucleases can induce splicing of the enzyme 
telomerase. Specifically the suggestion is that an mRNA transcript is produced from the 
complimentary strand, which is then digested forming a 47-mer oligonucleotide which binds at an 
intron exon junction – causing alternative splicing (76).  
Finally, expression and function of splicing factors seems to be under the control of “master 
regulators” including Tra2β (77) Nova 1 (78), ERK and AKT which, through downstream kinase and 
phosphatase action, induce or prevent the binding of the transacting elements (79) . Investigation into 
the downstream targets of these pathways has yielded further potential points of intervention. 
Latorre et al. demonstrate that splicing factors can themselves be up-regulated, using the downstream 
targets or ERK and AKT, FOXO1 and ETV6 (80). 
 It stands to reason then, if the spliceosome is the most complex molecular machine in the cell, that 
95% of the human genome is alternatively spliced, and master regulators control the elements of this 
splicing process, the potential ramifications of perturbations in the function or levels of these master 
regulators could be drastic.  
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1.3 DISRUPTED SPLICING IN THE AGEING BRAIN 
 
1.3.1 The genetics of neurodegenerative disorders 
Splicing disrupting mutations are those that through variants in the genetic sequence cause changes 
in the pattern of exon or intron usage (81). These are proposed to cause up to one third of all disease-
causing mutations (82, 83). For the majority of cases however, there is not a single gene cause, with 
genetic variation in multiple loci and environmental factors being associated with these conditions 
(84).  
Genome wide association studies (GWAS) are a powerful tool to identify genetic susceptibility factors 
for disease (85). GWAS studies have been employed to detect associations between common genetic 
variation and NDDs such as AD  (86) ALS (87) PD(88) and for age of onset in HD (89). Reviews of all of 
the GWAS studies conducted since 2007, show a large number of associated loci, with all but one 
indicating APOEε4 confirmed as the most significant risk factor (90) which accounts for up to 50% of 
cases of late-onset AD (91). In 2013, meta-analysis of GWAS studies found 19 additional loci reaching 
genome wide significance (P<5X10-8) additional loci for AD (92) and 24 additional loci for PD (93).  
GWAS studies also provide a foundation for investigation into treatment responses, allowing 
personalisation of therapeutic interventions in AD (94). Both monogenic (single gene) and 
multifactorial inheritance patterns for NDDs have been identified (95).  Mutations in the following 
genes: Presenillin 1 (PSEN1) (96), α-synuclein (SNCA) (97), β-synuclein (SNCB), microtubule associated 
protein (MAPT) (98), Amyloid precursor protein (APP) (99) Huntingtin (HTT) (100), and Glial fibrillary 
acidic protein (GFAP) (101)  are known to be monogenic causes of neurodegenerative diseases which 
demonstrate Mendelian patterns of inheritance within families. 
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1.3.2 Complex splicing patterns in the human brain 
The brain shows some of the most complex patterns of alternative splicing (102). This is exemplified 
by the neurexin3 (NRXN3) gene. Neurexins are pre-synaptic extracellular scaffold proteins, and the 
balance of their numerous isoform types is imperative for normal synapse formation and 
transmission(103). NRXN3 was originally believed to be capable of producing over 2000 different 
mRNA isoforms (104), although more recent studies suggest even this may have been an 
underestimate (103). The importance of the balance of the isoform ratio is a common theme 
throughout the transcriptome, both temporally and spatially (105, 106), and as such, control of 
isoform production is held under tight regulation (107).  
Governance of alternative splicing through proteins such as Ptbp1 and Rbfox family members can 
control cellular differentiation fate in the development stages of the brain (108). Other examples 
include the Aquaporin 4 (AQP4) M1/M23 transcripts, the ratios of which ensure that osmosis occurs 
at a finely controlled rate to ensure homeostasis is maintained (109) (110). The Leucine rich repeat 
kinase 2 (LRRK2) gene has multiple isoforms produced by differential splicing of its 51 exons which 
because of different activities are preferentially transcribed in different tissues (111). Exons 5, is 
spliced out for the transcript occurring in astrocytes whereas the truncated  exon 42a is produced in 
neurons and astrocytes, but is virtually undetectable in microglia (111). These are only a few examples 
of the importance of alternative splicing in the brain, the full complexity of which poorly understood. 
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1.3.3 Splicing dysregulation in neurodegenerative disorders 
The potential for point mutations to disrupt the cis-acting regulatory elements of specific genes means 
that splicing disruption is common in disease (112). Splicing regulator genes have themselves been 
directly linked to NDDs (113). In addition, mutations in trans-acting elements, which bind to these will 
also cause disruption, but on a much larger scale, as these trans-factors are involved in the splicing of 
vast number of genes (114). 
These trans-factor mutations cause metabolic and developmental problems (115) (114) and are 
sometimes lethal, as each splice factor will interact with cis-acting elements across a variety of genes 
(116).  Similarly, if ageing or pathogenic processes disrupt the regulatory kinases and phosphatases 
directly linked to the activation and localisation of splicing factors, similar outcomes can occur as 
canonical splicing is dysregulated (117, 118). This is especially true of neurodegenerative disease (119) 
(120).  Splice factors themselves are subject to further regulation through the action of phosphorylases 
and kinases. Phosphorylation of the SR and hnRNP proteins releases them from the cytoplasmic 
speckles in which they are normally localised (121), freeing them up to interact with the pre-RNA 
transcripts in the nucleus (122).  
 Examples of perturbation of such networks can be observed in existing cases of NDD’s: alternative 
splicing of exon 10 of the MAPT mRNA, brings about two specific isoforms, termed 3R (inclusive of 
exon 10) and 4R (exclusive of exon 10) (123).  Dysregulation of the MAPT splicing regulatory network 
and associated aggregation of pathological Tau, has been reported as a result of different phenomena. 
They include those caused by age-related and inflammatory mechanisms, aberrant activity of the 
regulatory kinases, and point mutations (120, 124). An example of pathogenicity resulting from 
phosphorylation status regulation in NDD’s can be seen in the mechanism of Cdc2- like kinases (CLK) 
1, 2, 3, and 4, which regulate exon 10 usage in Tau splicing through kinase action on SR proteins (125). 
Disruption of the exon 10 usage through CLK dysfunction produces imbalance between the Tau 3R 
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and 4R ratios, implicated in the development of AD (118).  This is just one example, demonstrative of 
the ubiquitous presence and importance of alternative splicing throughout so many mechanisms and 
pathways in the cell, and how disruption at any stage can be catastrophic. Moreover, changes in 
transcriptional activity of essential splicing factors in peripheral whole blood is correlated phenotypes 
known to be associated with unsuccessful ageing such as decreased grip strength, and reduced 
performance on cognitive functions tests, believed to be mediated by the dysregulation of splicing 
(126). 
1.3.4 Brain Inflammation and splicing regulation 
The complex regulatory network between ageing, inflammation, splicing dysregulation and the 
development of NDDs is beginning to be unpicked, but there is still much to be done. Splicing factor 
activity is regulated by SRPK protein kinases and by FOXO1 and ETV6 via ERK/AKT signalling  (127) (38, 
128). Interestingly, initiation of inflammatory signalling of the SASP is brought about through NFB 
pathway (129), which is also affected by the ERK and AKT signalling pathways (129). As a practical 
example, in mouse models of age related NDDs, increased transcription of inflammatory genes has 
been observed to correlate with subsequent dysregulation of the entire transcriptome and in addition 
dysregulation of alternative splicing and isoforms which affects synaptic plasticity (130).   
Neuroinflammation is known to be linked to the development of NDDs, and can be brought about by 
a number of factors (131). GWAS studies have linked the innate immune system to sporadic AD 
development, indicating a link between neuroinflammation and AD related dementia pathophysiology 
(132). Review of the literature suggests inflammation drives neuronal damage, which triggers 
inflammation as part of a vicious cycle, and targeting neuroinflammation may provide an opportunity 
to treat AD (133). Similar findings are present in reviews of literature for ALS (134) and PD (135) in 
both of which microglia and astrocytes are activated in a similar manner to AD (128, 129).  Splicing is 
also influenced by many factors which can include specific infectious agents such as Mycobacterium 
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tuberculosis (136).  The adenovirus is another known pathogen which dysregulates splicing , which it 
achieves by taking over host cell splicing machinery, by dephosphorylating splicing factors; inhibiting 
endogenous splicing (137). Pathogens have been linked to the initiation of NDDs (13) which has been 
correlated with their severe dysregulation of alternative splicing (138) (139).  
1.3.5 Brain stress response and splicing regulation  
The brain is exquisitely sensitive to cellular stress. It is the most metabolically active organ in the body, 
and as such, has a high output of factors such as reactive oxygen species (140). Splicing regulators are 
also known to be very responsive to cellular stress (31) and represent a crucial part of the organism’s 
repertoire of homeostatic mechanisms for dealing with changes in internal and external environment 
(141). Cholinergic hyper-activation brought about by physical or psychological stress in the CNS, brings 
about transcriptional activation and pre-mRNA splicing shifts (142, 143). In addition, changes in the 
RNA splicing of AChE transcripts has brain-to-blood effects, and can trigger neuronal – immune 
communication (144). Interestingly, suppression of these transcripts can reduce pro-inflammatory 
cytokine expression (144). Physiological stressors such as genotoxic agents, can induce changes in 
splicing patterns as a response to stress (145). For example, genotoxic stress can change the function 
of MDM2 transcripts, promoting p53 activity in response to this stress (145). These stress-induced, 
splicing pattern changes can have a range of functions including producing non-productive variants to 
counter transcriptional upregulation, or alternatively the can induce apoptosis and senescence (145) 
(146). 
 
1.3.6 Links between age-related changes and changes associated with neurodegenerative disorders 
Age related changes which occur in the brain, often predispose to both neurodegeneration and to 
NDD’s (147). These exist as both the accumulation of cellular and molecular damage, alongside 
breakdown in regulatory mechanisms (148, 149) and decline in the ability of the cells compensatory 
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mechanisms (147). As technology evolves allowing us to quantify the transcriptional changes common 
to ageing and to NDDs, interesting correlations begin to become apparent. Changes in alternative 
splicing patterns which are present in aged individuals are also present in those with a confirmed 
diagnosis of FTLD/AD, the difference in pattern is often only of magnitude (113). This may be due to 
age-related dysregulation of components of the core splicing machinery; activity levels of 
polypyrimidine tract binding protein (PTB) which aids in splice acceptor site recognition, was found to 
be consistent with these linked transcripts (113). Transcriptional changes directly linked to disorders, 
but not to age however, were consistent with decreased neuro-oncological ventral antigen (NOVA)–
dependent splicing regulation (113).  
The dysregulation of alternative splicing then, can come about by several mechanisms, and the 
subsequent effects in the brain are especially damaging. In an effort to unpick the problems, candidate 
genes known to be linked to the development of NDDs have been assessed for the production of 
multiple transcripts and for associated dysregulation of their concentration (150, 151). In AD, the 
delicate balance of isoforms with exon 10 inclusion/exclusion has been extensively explored and its 
dysregulation linked to the development of AD (152). In PD too, alternative splicing of a number of 
genes has been found to be linked to its pathogenic course (151).  
Dysregulation of splicing is almost ubiquitous amongst NDD’s. In AD, and Lewy Body Dementia, the 
presence of splice variants lacking the 7th and 9th exon of the glutamate transporter EAAT2 appear to 
contribute to excitotoxicity, causing neurodegeneration (153), suggesting a common pathway of 
dysregulation. Mutations in the valosin-containing protein (VCP) gene was demonstrated to have a 
central role in development of ALS, mediated by premature intron retention in developmental stages 
(154) Glial fibrillary acidic protein, the primary intermediate filament in astrocytes, has alternative 
isoforms present in Alexanders disease (155), and an upregulation of normally low abundance 
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isoforms in AD – a phenomenon which has been tightly associated with increased plaque load(156). 
Some more specific examples are included below. 
1.3.7 Alzheimer’s Disease 
Whole transcriptome analysis has provided evidence of large-scale changes across the transcriptome 
in Alzheimer’s Disease (AD), with over twenty-seven thousand unique transcripts being reported in an 
AD brain (157). Genes involved in the pathogenesis of AD commonly have alternative splice variants, 
Amyloid Beta Precursor Protein Binding Family B Member 2 (APBB2) , RNA binding fox homologue, 
(RBFOX), Presenilin1 (PSEN1), Presenilin 2 (PSEN2), and Apolipoprotein E (APOE), have all been 
reported to have alternative transcripts which have been suggested to result in the aggregation of β-
amyloid (150). Large scale splicing dysregulation has also been reported to create protein aggregates 
of many more types than previously believed. Using immunohistochemical analysis, core spliceosomal 
proteins such as the U1 snRNP were found to form aggregates themselves, implicating abnormal 
splicing more globally in AD pathogenesis (158).  The brains normal splicing regulation appears to be 
particularly reliant on the splicing factor NOVA, and many of the dysregulated transcripts are targets 
of this protein (113). Decreases in levels of some neurotransmitters such as choline, which are 
associated with progressive AD, can also lead to decreases in the translation of splicing factor 
transcripts via the Nonsense-mediated decay (NMD) pathway (159).  
Point mutations in splice donor sites in specific genes such as Amyloid precursor protein (APP), 
Presenilin1 (PSEN1) and Presenilin2 (PSEN2) genes have also been reported to produce aberrant 
transcripts that are also associated with -amyloid aggregates (160-163).  An intron inclusion 
transcript produced by an autosomal dominant PSEN1 mutation has been causally linked to AD (162). 
The gene encoding the microtubule associated-protein Tau (MAPT), a major component of 
neurofibrillary tangles, also produces multiple transcripts, the balance of which has been heavily 
implicated in AD (123). Tau protein functionality is dependent upon its phosphorylation status, hyper-
Alternative splicing and age-related neurodegeneration – Jed Lye 
Page 29 of 86 
 
phosphorylated Tau prevents its canonical role of binding to and stabilising microtubules (123).  
Mutations in the progranulin (GRN) gene, which encodes a pleiotropic anti-inflammatory protein, 
which has canonical neuronal protective effects, have also been linked to frontotemporal lobar 
degeneration (FTLD) (164-166). Aberrant splicing events around the first exon of GRN, leading to the 
introduction of premature termination codons, can lead to transcript degradation via the Nonsense-
mediated decay (NMD) pathway with associated loss of neuroprotective benefits (167) (168). The 
APOE gene is one which has been thoroughly investigated after getting multiple GWAS hits but no 
splicing dysregulation has been reported for this gene in the brain of AD (169), however its receptor 
APOER2 has been demonstrated to be dysregulated in both mouse and man (170) and restoration of 
correct splicing patterns was effective in preventing this mechanism of pathology (170). 
1.3.8 Parkinson’s disease 
Whole transcriptome studies in PD have been mildly less successful in producing inter-study 
concordance; with no specific genes transcripts being ubiquitously de-regulated (171) (172). Grouping 
the significantly changed transcription levels into pathway groups however circumvents this problem 
(172). 
-synuclein (SNCA) gene has also been associated age at onset and disease progression in PD. SNCA 
produces several alternatively expressed isoforms, 4 of which are usually found only at low levels in 
unaffected brain.  These isoforms have been reported to be overexpressed in different patterns in PD 
depending on the locality of the neurodegeneration (173-175). The same transcripts are also noted to 
be dysregulated in other NDDs, such as dementia with Lewy bodies and AD (176) (173, 177). It appears 
in some cases, that the presence of a known PD-associated SNP in the 3’ region of the SNCA gene 
drives higher ratios of one of the transcripts which is present in large amounts in affected individuals 
(178) indicating that a cis-regulatory element may have been disrupted. Mutations affecting splice 
acceptor sites have been recorded in cis elements of presenilin-1 gene (179). Aggregation of misfolded 
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α-synuclein is a primary factor in pathogenesis of PD and dementia with Lewy bodies (DWLB) (180). 
Its oligomerisation leads eventually to the production of the intracellular aggregate known as Lewy 
Bodies (181). Alternative splicing of the α-synuclein transcript is one way in which misfolding can occur 
and lead to aggregation (182). The build-up of α-synuclein appears to be caused by transmission from 
the gut to the brain (183). Other genes with notable dysregulation of splicing in PD include leucine-
rich repeat kinase 2 (LRRK2) implicated in neurite outgrowth, cytoskeletal integrity and autophagy. 
LRRK2 boasts 51 exons harbouring mutations which elicit effects through disrupted alternative 
splicing. In addition, vacuolar protein sorting 35 (VPS35), parkin RBR E3 ubiquitin ligase (PARK2) 
(implicated in mitophagy metabolism cell growth and survival), and PTEN induce putative kinase 1 
(PINK1).  
  
1.4 SPLICING MODIFIERS AS FUTURE THERAPEUTICS FOR NEURODEGENERATIVE DISEASE  
Whilst there are European Medical Association approved gene therapies now available for some 
genetic disorders such as GlyberaR® and Strimvelis®, much remains to be understood about the 
toxicity of these methodologies (184). Promising methods such as CRISPR/Cas9 technologies are still 
in very early stages, of investigation (184). Beyond gene therapy, three main points of intervention 
exist for tackling splicing. 1. Co-transcriptionally targeting RNA with complimentary sequences to 
modify access by splicing components, or  using RNAi to moderate levels of splicing factors, 2) 
Modulation of how RNA targets are recognised by modification of the binding proteins, 3) Modulation 
of the regulatory machinery which allow binding proteins to carry out splicing (185).  
Modification of splicing patterns using targeted oligonucleotides or antisense technologies has 
enormous potential for exploration as future therapies (186). Small interfering-RNA based approaches 
have shown significant potential in cancer treatment when targeting the protein’s kinases, which 
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directly affect the phosphorylation status and thus activity of splicing factors (187). The interactions 
between RNA binding proteins and RNA has been widely posited as a potential point for therapeutic 
intervention (113, 123, 188). However, the pharmaceuticals already in use with proven activity in the 
brain are non-selective (189), and so targeting specific interactions remains elusive. A more fruitful 
approach might lie in the identification of specific splicing changes with proven causality in driving 
neurodegenerative disease. Oligonucleotides which correct splicing dysregulation of the APOER2 gene 
in the region of exon 19, demonstrate dramatic effects in mouse models of AD (190). Similarly, the 
Klotho protein involved in age suppression and longevity (191) has two commonly known isoforms, a 
secreted (s-Kl), and a membrane bound (m-Kl) form, which are produced by AS. Injections of the 
secreted form increases cognitive function, learning and memory in mouse models (192). A further 
form can be created by cleavage of the membrane binding domain of the protein, resulting in a 
different secreted form (193). Pharmacological intervention in the form of small molecules has also 
showed promise for rectifying dysregulation which accompanies ageing in other cells lines (37), and 
based on the congruencies between many NDDs and ageing in regards to RNA splicing this may hold 
promise for NDD interventions. Once compounds have been validated as modulating splicing in in-
vitro studies, targeting them to the brain; a serious challenge – although one not without promising 
progress (194).  
Finally, the development of therapeutics that specifically targeted the senescent support cells in the 
brain (astrocytes and microglia) might be an avenue for exploration. Senescence modulation has been 
suggested as a method for tackling the root causes of the age-related decline. These approaches 
involve clearance of senescent cells (senolytics) (195) or reversal of elements of the senescence 
program (senostatics) (196).   
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1.4.1 Summary 
The hugely complicated process of alternative splicing is, because of this very nature of complexity 
potentially subject to so much error. In addition, as it is so ubiquitously involved with all the processes 
throughout the cell, when these errors occur, they will have far reaching consequences and in some 
cases be can be catastrophic. However, there is much promise as our technology and understanding 
advances further, and we can find enhanced methods of correcting the problems and re-balancing the 
delicate splicing process to combat disease and compress morbidity and delay mortality.  
The links between NDDs and alternative splicing are clear and strong, and research into splicing 
modulators is still in its infancy. Research continues to identify causal links to, and potential 
therapeutic targets for, NDDs. Given the colossal importance of alternative splicing to the 
maintenance of healthy ageing, and the shared and intimate links to NDDs, targeting alternative 
splicing and its regulation promises to yield valuable information and potential therapeutic 
interventions. The advancement of gene therapy techniques that target specific isoforms or selectively 
target components of the splicing regulatory machinery may herald a real and valuable step forward 
towards the next generation of anti-degenerative therapies.  
1.5 AIMS AND OBJECTIVES 
 
Alternative splicing is of great importance to normal cell functioning and age-related perturbations 
are intimately linked to age related disorders, which in brain can manifest as neurogenerative 
conditions and associated cognitive decline. Cellular senescence is an age-related phenomenon, which 
appears to be mediated, in part, by alternative splicing. The accumulation of these senescent cells 
brings about chronic paracrine inflammation, driving further dysregulation of normal cell function, 
alternative splicing and evoking further cellular senescence in surrounding tissues.  
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We hypothesised that the phenomenon of cellular senescence in the astrocytes of the brain, 
contributes to the development of neurodegenerative disorders and associated cognitive decline, and 
that this was mediated by the senescence associated secretory phenotype, dysregulation of splicing 
mechanics and subsequent changes in isoform production.  
We also considered, that if this was such, such isoform changes may be detectable in the blood, either 
through parallel changes in transcription organism wide, or through compromised integrity and 
breakdown in blood brain barrier, associated with age and NDDs. We aimed to create a senescent 
astrocyte population and characterise the associated secretory phenotype for this cell line. We then 
aimed to characterise splice factor dysregulation which occurs with cellular senescence and compare 
this with our characterised changes in isoforms of an a-priori gene panel in this cell line.  
Once this had been achieved in-vitro, we aimed to conduct cohort study in which we compared 
peripheral whole blood levels of the isoforms we had identified, and using multivariate regression, 
asses the association between changes in these levels over a time course, and the development of 
cognitive decline.  
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2 METHODS 
2.1 GENERAL METHODS 
 
2.1.1 In-Vitro investigation into astrocyte splicing dysregulation  
2.1.1.1 Cell culture  
These studies used cultures of early-passage and late-passage human primary astrocytes (HPA) 
previously isolated from a block of sub-ventricular deep white matter tissue in a 17-year-old male 
donor immediately post-mortem with consent from next-of-kin. Ethical approval was granted by the 
North and East Devon Research Ethics Committee. Astrocytes were isolated from tissue blocks as 
previously described (197).  
Human Primary astrocytes (HPA) were obtained from Celprogen (Celprogen Inc., Torrance, CA, USA) 
and at passage number 2. And cultured in-vitro. Cells were maintained in humidified incubators with 
95% O2/5% CO2 in HPA stock media (Celprogen Inc., Torrance, CA, USA). Cell culture was performed in 
T75 culture flasks coated with poly-L-lysine (Sigma Aldrich, UK). To coat flasks, poly-L-lysine was 
diluted to 1:1000 in PBS, 2ml of this mixture was added to the flasks for 30 minutes before being 
discarded and flasks sealed with parafilm and refrigerated until use. Cells were seeded at a density of 
400,000 cells per T75 flask.  Cells were cultured in 10ml Celprogen human astrocyte cell culture 
medium with serum (M36058 -01s). Human astrocyte cells were cultured until 75-80% confluence was 
reached.  Human astrocytes were washed twice with Dulbecco’s PBS (Sigma Aldrich, UK), treated with 
2ml 0.025% trypsin, neutralised with an equal amount of media, transferred to a flacon tube, pelleted 
using a centrifuge at 700xg resuspended in fresh media and counted. Counts were performed using 
the Biorad™, tc20 automated cell counter.  
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 3 cryovials of human astrocyte culture was frozen down at each passage. Cell freezing was performed 
with a freezing mixture of 700ul human serum (Celprogen Inc., Torrance, CA, USA) 200ul cells in 
medium and 100ul DMSO (Sigma Aldrich, UK). These were then placed in ‘Mr. Frosty’ tool, to reduce 
the rate of freezing and reduce crystal formation and placed in -800C freezer.  
For the production of senescent cultures, cells were counted, and equal numbers of cells seeded 
(4x103 cell/cm2) at each passage in continuous culture until the growth of the culture slowed to less 
than 0.5 population doublings (PD)/week. Astrocyte cultures underwent continuous culture until the 
onset of replicative senescence and growth arrest in 3 biological replicates. Early passage astrocytes 
at PD = 24 and late passage astrocytes at PD = 84 were used.  
 
2.1.2 Quantification of senescent cell load 
To quantify senescence in early and late passage astrocytes, 3 biological replicates were evaluated for 
activity of the biochemical senescence marker senescence-associated galactosidase (SA β-Gal) using 
a commercial kit (Sigma Aldrich, UK) according to manufacturer’s instructions, with a minimum of 100 
cells assessed per replicate.  
Briefly, cells were seeded into 6 well plates which had been ready -coated with Poly-L-lysine at a 
density of 60,000 cells per well and incubated in 2ml astrocyte media from Celprogen at 370C until 
these reached 75% confluence.  
At this point, media was aspirated off, cells were washed twice, and 1.5ml fixing solution was applied. 
Cells were then incubated for 5 minutes. Fixative was pipetted off, and cells were washed three times 
more with PBS, and finally 1.5 ml of staining solution (see Table 2.1) was added to each well. We 
noticed that if we followed the manufacturers guidelines and added a 2ml volume of the staining 
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solution to each well, the amount of blue stain produced by the cleavage reaction was too great and 
it was not possible to differentiate between those cells which were stained and those which were not. 
Amounts were reduced by 25%. 
Table 2.1 Staining solution reagents 
Reagent  Measure  
X-gal solution (pre-warmed) 0.25ml 
Reagent A 125ul 
Reagent B 125ul 
DDH2O 8.5ml 
 
Importantly the staining reaction is a redox reaction and particularly sensitive to changes in Ph. 
Manufacturer’s instructions including sealing the plate with parafilm and being sealed in a non-co2 
incubator.  Cells were then examined through microscopy and counts of stained cells were obtained 
and compared between young and old astrocytes to determine the overall levels of cellular 
senescence between samples.  
Senescence was also quantified by assessing the expression of the CDKN2A gene (a known molecular 
marker of cell senescence) and by changes in cell morphology typical of senescence as in our previous 
work (33, 37). Total RNA (100ng) was reverse transcribed in 20 µl reactions using EvoScript reverse 
transcriptase (Roche Life Sciences, Burgess Hill, UK). Total CDKN2A expression was measured by qRT-
PCR relative to 3 empirically-determined endogenous control genes (GUSB, PPIA and GADPH) on the 
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QuantStudio 12K Flex platform (Applied Biosystems, Foster City, USA). PCR reactions contained 2.5 µl 
TaqMan Universal Mastermix (no AMPerase) (Applied Biosystems, Foster City, USA), 900nM of each 
primer, 250nM probe and 0.5 µl cDNA in a total volume of 5 µl. Cycling conditions were a single cycle 
of 95 ºC for 10 minutes followed by 40 cycles of 95 ºC for 15 seconds and 60 ºC for 1 minute. 
2.1.2.1 Profiling of Senescence associated secretory phenotype in young and old cells 
Early and late passage human astrocytes were seeded in two biological replicates of 10x104 cells in a 
25cm2 flasks pre-lined with Poly-l-Lysine as described above at a density of 100,000 cells. After 
48hours incubation, cell supernatants were harvested and stored at -80°C. SASP was profiled using 
both ABCAM Human Cytokine Antibody Array (ab133997; Abcam, Cambridge, UK) and the ABCAM 
Human MMP Antibody Array (ab134004; Abcam, Cambridge, UK). SASP components measured were: 
IL-1B, IL-2, Il-6, IL-8, IL-10, TNF, IFN, GM-CSF, Angiogenin, ENA78, GRO, MMP3, MMP10 and 
TIMP2.  
 Cell membranes from the kits were blocked with supplied blocking buffer at room temperature for 
30 mins, before aspirating off blocking buffer. 1ml of media was then applied to each membrane and 
incubated for overnight at room temperature. Following overnight incubation, membranes were then 
washed for 30 minutes, in 20 ml of supplied wash buffer 1.  Six more subsequent washes of the 
membranes were then conducted, 3 each with both wash buffer 1, then wash buffer 2. Biotin-
conjugated anti-cytokines were then pipetted into each well and incubated for 2 hours, at room 
temperature. The anti-cytokines were then aspirated off, and the 6 washes with wash buffer 1 and 2 
were repeated. 2ml of HRP-conjugated streptavidin was then applied into each well, and the 
membranes were incubated for 2 hours at room temperature. 6 washes were then repeated once 
more, 3 each with wash buffer 1 and 2.  
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Membranes were transferred to tissue paper to dry. Excess buffer was removed by blotting the edges 
of the membrane with tissues paper, while preventing the membranes from drying out completely. 
Membranes were transferred to provided plastic sheet. 500µl of pre-mixed detection buffer C and 
detection buffer D were pipetted onto the membrane, taking care not to disrupt the reagents already 
bound to the membrane, and incubated for two minutes. A final plastic sheet was then applied to the 
top of the membrane surface, and membranes were imaged using Bio-Rad chemi-doc 
chemiluminescence. Images were interpreted using image J software, and the absorbance of each 
cytokine and MMP antibody was compared between the samples of media taken from old and young 
astrocyte cultures. Results were normalised using positive and negative controls as per the kit 
instructions using the LI-COR Odyssey CLx imaging system (Lincoln, NE, USA). An unpaired two tailed 
t-test was used to assess statistical significance in secreted matrix metalloproteinases and 
inflammatory cytokine secretion using Minitab 18 software package (Minitab, Centre County, USA). 
2.1.2.2  RNA extractions 
Cells were treated with 1ml trypsin for 1 minute, to detach from poly-L-lysine. Cells aspirated from the 
flasks and added to an Eppendorf tube. Trizol was added to lyse cells, and falcon was inverted 5 x and 
then incubated at room temperature for 5 minutes. 0.2 ml of chloroform was added, and tubes were 
shaken for 10 seconds and incubated at room temperature for a further 3 minutes. Falcons were then 
centrifuged at 12000 rpm for 15 minutes at 4oc. The aqueous phase is was then transferred to a fresh 
Eppendorf. 0.5ml of isopropanol was then added to the solution, to facilitate the precipitation of the 
RNA, and this was left overnight. 24 hours later, samples are centrifuged at 12000 rpm for 10 minutes 
to form a pellet. Supernatant was then pipetted off, and 1ml of 75% ethanol was added to wash the 
pellet. RNA was then pelleted again by centrifugation at 1200 x G for a further 30 minutes, this is then 
resuspended in 500ul 75% ethanol. This Eppendorf is then left open, for the ethanol to evaporate, and 
finally the RNA is then diluted in 10ul RNase free water.  
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2.1.2.3 Reverse Transcriptions 
Reverse transcriptions were carried out using The SuperScript VILO cDNA Synthesis Kit, (Thermo 
Fisher Scientific, Warrington, UK). All regents were mixed on ice. Primarily, 2µl of 10x superscript 
enzyme mix was combined with 5x VILO reaction mix, 2ul RNA (with total amount of RNA being 100ng), 
and 11 ul of DDH2O. Mix was then incubated at 25oC, for 10 minutes (annealing step), followed by 42 
oC for 60 minutes (extension step), and finally 85 oC for 5 minutes (denaturation step). 
 
2.1.3 Quantification of splicing factor expression 
Splicing factors have previously been demonstrated to be associated with cellular senescence with 
evidence suggesting they may be drivers of this process in some tissues (37-39). We measured the 
expression levels of an a priori panel of 20 splicing factors previously associated with age, lifespan, 
cellular senescence in different tissue types in our previous work (32-34). This panel included the 
splicing inhibitors HNRNPA0, HNRNPA1, HNRNPA2B1, HNRNPD, HNRNPH3, HNRNPK, HNRNPM, 
HNRNPUL2, the splicing activators AKAP17A, PNISR, SRSF1, SRSF2, SRSF3, SRSF6, TRA2B, SRSF7 and 
the SF3B1, IMP3, LSM14A, and LSM2 components of the core spliceosome. Splicing factor expression 
was measured in 3 biological and 2 technical replicates by qRT-PCR using custom TaqMan Low Density 
Arrays (TLDA) on the Quantstudio 12K Flex platform as previously described (33). Transcript levels 
were expressed relative to the geometric mean of the GUSB and PPIA endogenous control genes and 
normalised to their expression in RNA from early passage cells. We then performed tests for equality 
of variance and t-test using IBM SPSS Statistics 25.  
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2.1.4 Quantification of candidate gene expression in early passage and senescent astrocytes 
A panel of candidate genes were selected for analysis on the basis of biological relevance; known links 
with brain function, neurodegenerative disease or senescence, and where available, evidence from 
the literature that alternatively expressed isoforms may have differential function to allow 
interpretation of changes. The identity of genes tested, and brief description of function is given in 
Table 2.2. 
 TaqMan Assays specific to isoforms were designed to unique regions of the transcripts in question 
(assay sequences are available upon request). Assays were validated by standard curve analysis using 
7 serial 1:2 dilutions of cDNA derived from whole brain lysate. Reverse transcription and qRT-PCR 
conditions are described above. Experiments were carried out in 3 biological and 3 technical 
replicates. Again, transcript levels were expressed relative to GUSB and PPIA endogenous control 
genes and normalised to their expression in RNA from early passage cells. We then performed tests 
for equality of variance and t-test using IBM SPSS Statistics 25.  
 
Table 2.2– Transcript isoforms identified for expression analysis. 
The table gives the identity of the isoforms selected for analysis, the relevant NM accession numbers 
and a brief description of their function. 
 
Gene 
Transcript Accession Isoform/transcript function 
ATM 
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AQP4M23 




NM_004171.4 Excitatory amino acid 
transporter 
EAAT2B 




NM_002055 Astrocyte intermediate 
filament protein 
GFAP(B) 




NM_004795 Membrane bound isoform, 
coreceptor for FGF23 
KLOTHO msKl 
NM_004795.3  Secreted isoform, endocrine 
factor which improves 




NM_058195 p53 pathway to cell cycle 
cessation  
p16INK4A 
NM_001195132 RB1 pathway to cell cycle 
cessation (198) 
CDKN1A 
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p21a 
NM_078467 Inhibits proliferation 
 
p21b 









Cell cycle regulation 
 
PSEN2 





Microtubule protein involved 





Microtubule protein involved 
in neurofibrillary tangles  
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Probes were designed by obtaining the genomic sequence of the transcripts using the UCSC Genome 
browser database and performing in-silico splicing of the sequence and designing probes bridging 
specific exons boundaries which only existed in the target isoforms, these were ordered from 
Thermofisher™. In the case that Thermofisher™ had off-the-shelf probes ready designed for an 
isoform species, these were ordered and efficiency of 100% was assumed; therefore these probes 
have values which appear blank in the table. Probe binding efficiency was validated via QPCR standard 
curve in whole blood (Table 2.3) Differential expression of the candidate isoforms in young and old 
primary astrocyte cell lines were measured using qRT-PCR, and expression changes were calculated 
using the ΔΔCT method, which is explained below.  
Table 2.3 Standard curve binding efficiency assay 
All probes had binding efficiency over the pre-designated threshold of 80% except for P2SV which did 
not successfully bind and was subsequently removed from the study. Gradients lower than -3.32 
indicate less than 100% efficiency. R2 values are indicative of pipetting error, with a value of 1 being 
ideal. The values were deemed to be acceptable. 
Gene Slope y R2 Binding efficiency 
p53    100 
ATM    100 
GADPH    100 
Gfapa -3.563 30.347 0.999 90.823 
gusb    100 
mKlotho -3.882 38.348 0.947 80.959  
p14    100 
P16    100 
p21b    100 
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p53    100 
ppia    100 
PSEN2 -3.663 34.477 0.995 87.49 
P2SV 0 0 0 0 
sKLOTHO -3.589 37.363 0.983 89.956 
tau3 -3.792 35.832 0.991 83.53 
tau4 -3.8 31.594 0.94 83.307 
 
2.1.4.1 ∆∆Ct method 
We trialled 3 common housekeeping genes PP1A, GUSB and GAPDH for comparison in expression 
changes across the candidate gene list. Once qRTPCR had been conducted we used the online tool ref-
finder (decommissioned) to ascertain which method of normalisation would be optimal based on the 
stability of expression. Methods trialled were each of the housekeeping genes (HKG’s) individually, 
combinations of two HKG’s, all three HKG’s, geomean of all samples, geomean of all samples plus 
HKG’s Geomean of all samples, plus combinations of two HKG’s and geomean of all samples plus 
individual HKG’s. It was determined that the most stable baseline for control was the geomean of all 
samples, plus PP1A and GUSB. GAPDH was observed to be very unstable in our astrocyte samples and 
was removed from all analysis. When calculating the differences between the cycle threshold (CT) of 
baseline expression and the expression of each sample, we used the median values of the triplicates 
to mitigate the effect of any outliers. The difference (∆) between CT of baseline and RNA isoform was 
compared for both young and old astrocytes (∆∆Ct), and log base 2 was taken of these values to derive 
fold change, this is the basis for the semi- quantitative 2∆∆Ct method which is used for deriving the 
relative abundance of gene or isoform expression.   
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2.1.5 Assessment of candidate gene expression levels with cognitive decline in a longitudinal human 
population 
The temporal study of cognitive decline and associated factors requires a study length beyond that of 
the allotted time of the current study. We have therefore made use of the epidemiological prospective 
population-based “InCHIANTI” study. Inverchiare in Chianti (ageing in the Chianti area) is an in-depth 
cohort study, providing the data from people of age range 20-102 years living in the Chianti geographic 
area (Tuscany, Italy) with detailed assessment of health and lifestyle parameters at baseline, and again 
at 4 subsequent follow-ups (FU2; 2004 – 2006, FU3; 2007 – 2009 and FU4; 2012 - 2014) (199).  
The study’s principal investigator Dr. Luigi Ferrucci initiated the study in 1998, supported by a grant 
from the National Institute on Ageing. The study was designed to enhance comprehension of the risk 
factors for age related disorders later in life, and to produce a standardised schematic for metric 
detailing and observation relating to ageing and associated pathologies. Physiological factors, which 
affect age related pathology, were broken down into 6 subsystems: the central nervous system, the 
peripheral nervous system, the perceptual system, muscles, bone-joints, and energy 
production/delivery. Basal data collection started in 1998 and was completed in 2000, with follow-ups 
of each participant every 3 years subsequently. These time-point intersections at which data was 
collected and clinical examinations were conducted were termed “waves”. The examination included 
vast amounts of survey questions about lifestyle, diet, education, background, physical health, and 
involved acquisition of samples of blood for analysis. 
For the initial study, samples were obtained from two specific areas – one urban (Greve in Chianti) 
with a population of 11,709 inhabitants of which 19.3% are 65+, and one rural (Bango a Ripoli) with 
4704 inhabitants of which 20.3% were 65+. A two-stage sampling procedure was used at both to 
obtain representative samples. Initially, 650 persons over the age of 65 were selected from the 
population registry, with the caveat of Italian birth being a pre-requisite for study inclusion. In 
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addition, 50 men and 50 women were then selected randomly from each 10-year age group from 20 
to 59, with 10 men and women from the age group 60-64.  
We selected 197 participants from this cohort for study. Inclusion criteria were age at FU3 > 64 years 
with an MMSE score > 18 to avoid those already on a declining cognitive trajectory and availability of 
an FU3 RNA sample with clinical information available at both FU3 and FU4. Participants were 
categorized into ‘mild’ or ‘severe’ groups depending their change in the MMSE score between FU3 
and FU4; individuals declining between 2 and 8 points were defined as ‘mild’ whereas those declining 
between 9 and 22 points were categorised as ‘severe’. These thresholds were chosen on the basis of 
previously defined criteria where a ‘severe’ decline was categorised as a drop in MMSE score > 3 points 
per annum (200-202). Ethical approval was granted by the Instituto Nazionale Riposo e Cura Anziani 
institutional review board in Italy. Methods were carried out in accordance with the relevant 
guidelines and regulations. Informed consent was obtained from all participants. 
2.1.6 Blood Collection 
Peripheral Blood samples were collected from 700 of the participants within 3 weeks of the 9-year 
follow up interview. Participants were instructed to fast for at least 8hrs prior to collection.  2.5ML 
peripheral whole blood was collected into PAXgene tubes (BD Biosciences) at wave 9 and wave 12 and 
frozen at -80oC and RNA was extracted using the PAXgene blood RNA kit (Qiagen, Paisley, UK) as per 
manufacturer’s instructions.  
RNA extractions were performed using the Pre-analytix whole blood RNA extraction kit on the whole 
blood of samples obtained from individuals from the InChianti cohort at the two separate time points 
(wave 9 and wave 12). Reverse transcriptions were carried out on 100ng RNA using the EvoScript™ 
Universal cDNA Master kit (Roche Life Sciences, Burgess Hill, UK) according to the manufacturer’s 
instructions except for a change to the extension phase of the reaction: a step of 30 minutes at 65°C 
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was used instead of 15 minutes at 65°C. reactions were set up in a nuclease free environment, and 
placed on ice. Reagents were added to the Eppendorf in according to manufacturer’s instructions (see 
Table 2.4). The enzyme mix was added last, before which all reagents were vortexed.  
Table 2.4 RTPCR reaction mix 
Reagent  Volume  
Water Make up to 18ul 
Reaction buffer 4ul 
Template RNA 100ng 
Enzyme Mix 2ul 
RtPCR thermocycler was set up as follows:  
 42°C for 15 minutes.  
 85°C for 5 minutes.  
 65°C for 30 minutes. 
 4°C with an unlimited Hold time. 
 Concentration of DNA was assessed using the Thermo Scientific NanoDrop 2000. We then assessed 
expression of transcripts which had observed senescence-related dysregulation in levels in-vitro in 
peripheral blood. These were GFAPa, Mklotho, Tau3, PSEN2, P14, P16, P21a and P21b. Relative 
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expression of mRNA isoforms was measured through qRTPCR. This was achieved using 96well plates 
on the Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR System. Samples were run in 
triplicate; batch effect was corrected for by cross plate normalisation to control samples.  
We then investigated the association between transcript expression and cognitive decline as 
measured by change ( in mini mental state exam (MMSE) score. The MMSE was developed by 
Folstein and Folstein in 1975 as a method to assign quantifiable metrics to the intellectual abilities and 
deterioration thereof in patients. It has become the most common clinically utilised test of cognitive 
function (203). The MMSE takes around 10 minutes to complete, consists of both verbal and written 
participation and measure orientation, registration, attention calculation recall and language (204). It 
also has a higher sensitivity than other commonly used assessments (205).  
To conduct our analysis we organised the samples into two groups, those with a mild cognitive decline; 
as evidenced by a decrease in MMSE score of between 2 and 8 points over a 3-7 year period, or those 
with severe decline which was represented as a reduction of 9-22 points during that same period. 
 A mild reduction was classified as a reduction of 2-8 points in MMSE performance over a 3-7-year 
period or severe decline. Severe reduction classification was a reduction of 9-22 points in MMSE 
performance over the same period.  Using multivariate linear regression models with age, gender, 
smoking (lifetime pack-years), study-site, education level and white blood cell subtype counts (% 
neutrophils, monocytes, basophils, eosinophils) entered as confounding factors. 
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3 RESULTS  
Introduction 
We hypothesised that senescent astrocytes would display differential expression of splicing regulatory 
factors and altered patterns of alternative splicing in vitro, and that some of these isoform changes 
may be detectable in peripheral blood and show statistical associations with cognitive phenotypes in 
human populations.  
We first characterized the astrocyte SASP in terms of cytokine and MMP production, and then 
determined the splicing factor repertoire and patterns of alternative splicing for a panel of brain or 
senescence candidate genes in senescent human primary astrocytes. Where dysregulation of splicing 
patterns was demonstrated and expression was conserved in blood, we then assessed associations 
between peripheral blood isoform levels and measures of cognitive dysfunction from 197 individuals 
from the InCHIANTI study of aging, a longitudinal and cross-sectional population study of individuals 
from the Tuscany region of Italy (199). We identified that senescent astrocytes display a modified 
SASP, consisting of elevated IL8, MMP, MMP10 and TIMP2 levels, but decreased IL10. 50% of splicing 
regulatory factors tested demonstrated dysregulated expression in senescent astrocytes; this was 
accompanied by altered splicing of 7/13 of candidate genes tested. Furthermore, when we assessed 
the relationship between peripheral blood expression of isoforms dysregulated in astrocytes and 
cognitive decline as measured my Mini Mental State Exam (MMSE), GFAPα and TAU3 transcript levels 
were positively correlated with cognitive decline, whereas GFAPΑ transcript levels were negatively-
associated with cognitive decline over a 3-7 year period in participants from the InCHIANTI study of 
aging. Our data agree with the hypothesis that senescent astrocytes display differential expression of 
splicing regulatory factors and altered patterns of alternative splicing, and that some of these isoform 
changes may reflect those in peripheral blood. Such changes may show statistical associations with 
cognitive phenotypes in human populations.  
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3.1.1 Characterization of senescent astrocytes 
Human primary astrocyte cultures were passaged until PD84 at which point they were considered 
senescent. This was verified by molecular and biochemical characterisation of the growth kinetics of 
the cultures; senescence associated β-galactosidase (SA--gal) staining demonstrated a significant 
increase in the number of senescent cells from 8% in early passage cells to 36% in late passage cells 
(Figure 3.1 A) which was mirrored by a concurrent increase in the expression of the CDKN2A gene 
Figure 3.1 B). SASP factors in conditioned media derived from senescent cells demonstrated altered 
levels for several key SASP proteins; we observed elevated IL-8, GM-CSF, Angiogenin, ENA78, GRO-, 
MMP-3, MMP-10 and TIMP2 levels (Table 3.1, Table 3.2, Figure 3.2, Figure 3.3). Several other changes 
in SASP profile were also seen to be approaching statistical significance; IL-12, MCP-2 and MIP-1o all 
saw increases in secretion at levels approaching P=0.05.  
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Figure 3.1 Senescence validation 
Change in senescent cell load as determined by senescence-associated -galactosidase (SA--
Gal) staining between early passage and late passage human primary astrocytes. The percentage 
of cells staining positive for SA--Gal is given on the Y axis, and the identity of the cell culture on 
the X axis. Early passage cells are population doubling (PD) 24, late passage cells are at PD = 84. 
Results are from 3 biological replicates. * = p<0.01, **=p<0.01, ***=P<0.001. Error bars refer to 
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Table 3.1  Profiling the senescence associated secretory phenotype in astrocytes - Cytokines 
Table shows Gene ID, mean cytokine secretion in-vitro for young (Y) and old (O) astrocytes in arbitrary 
units, standard deviation, log-base 2 of fold change (n=6). T values and P values. Statistically significant 
(P <0.05) changes are denoted by * and row is shown in bold typeface, highlighted grey. Those 
approaching but not meeting statistical significance are shown in in bold typeface. 
 
Gene  Mean Y SD  Mean O  SD Log 
2FC 
T  p 
ENA78 160.6179 54.7 270.2554 54.7 0.75 -2.76 0.033* 
GM-CSF 27.05994 7.63 66.12956 15.3 1.29 -4.58 0.04* 
GRO 442.2389 134 528.5193 94.7 0.26 -1.05 0.334 
GRO-a 256.1518 55.6 461.5086 130.2 0.85 -2.902 0.027* 
I-309 56.35094 17.0 53.72426 32.7 -0.07 0.125 0.905 
IL-1a 79.76639 25.7 76.30872 17.3 -0.06 0.224 0.831 
IL-1b 274.2334 48.7 286.058 73.6 0.06 0.27 0.798 
IL-2 74.65903 48.0 111.5412 37.9 0.58 1.21 0.273 
IL-3 258.89 58.7 293.8777 58.7 0.18 0.98 0.363 
IL-4 99.51305 11.2 120.0094 17.0 0.278 2.01 0.091 
IL-5 91.63144 4.1 63.09812 37.6 0.54 1.508 0.182 
IL-6 78.75196 23.6 73.4896 19.0 -0.10 3.47 0.740 
IL-7 84.55205 27.3 84.66937 29.0 0.00 -0.06 0.995 
IL-8 409.5415 111.9 1097.73 256.3 1.42 -4.921 0.003** 
IL-10 56.5598 19.1 18.21913 9.6 -1.63 3.595 0.11 
IL-12p40/P70 144.4992 32.2 213.145 55.9 0.56 -2.131 0.077 
IL-15 148.8075 40.6 186.7788 43.8 0.33 -1.272 0.251 
IFN-y 120.7869 40.1 137.9333 47.8 0.19 -.550 0.602 
MCP-1 13789.02 2275.5 14939.13 4300.9 0.12 -.473 0.653 
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MCP-2 243.1771 53.8 325.7858 51.0 0.42 -2.230 0.067 
MCP-3 84.43644 26.2 108.8109 34.6 0.37 -1.122 0.305 
MCSF 329.5096 59.6 374.0884 57.7 0.18 -1.075 0.324 
MDC 313.7771 42.9 339.8177 97.7 0.12 -.488 0.643 
MIG 45.36578 25.8 55.28631 49.0 0.29 -.358 0.732 
MIP-1o 172.7754 30.9 235.2977 53.1 0.45 -2.035 0.088 
RANTES 483.5395 108.8 573.9288 150.5 0.25 -.973 0.368 
SCF 250.5389 56.4 293.2824 95.3 0.23 -.772 0.469 
SDF-1 467.7116 140.7 394.8161 153.0 0.24 .702 0.509 
TART 325.1283 44.7 399.2366 96.1 0.30 -1.398 0.211 
TGF-b1 177.1489 25.1 253.0473 103.0 0.51 -1.432 0.202 
TNF-a 10.21346 11.3 16.81171 16.2 0.72 -.598 0.576 
TNG-b 219.506 131.6 126.9624 19.4 0.79 1.392 0.213 
EGF 144.5994 32.3 132.2963 75.2 0.13 .301 0.774 
IGF-1 131.1638 50.4 167.6447 36.5 0.35 -1.173 0.258 
Angiogenin 881.4542 213.9 1397.67 206.7 0.67 -3.471 0.13 
Oncostatin M 1157.461 256.7 950.4137 129.2 0.28 1.441- 0.200 
Thrombopoietin 249.2383 69.8 312.3784 62.4 0.33 1.349 0.226 
VEGF 376.0153 92.0 483.9697 89.2 0.36 -1.685 0.143 
PDGF BB 230.6906 73.9 231.5844 35.6 0.01 -.022 0.984 
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Figure 3.2 Key SASP cytokines as measured by ELISA  
Figure displays data for key SASP cytokines based on those which demonstrate significant changes in 
the current research and those which have evidence of significance from previous research (79, 
206). The changes observed in secreted cytokines in young (light grey bars) and old (dark grey bars) 
astrocytes (N=6). Statistically significant changes were notes in IL-8 (P<0.005) and IL-10, GM-CSF, 
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Table 3.2 Matrix Metalloproteinase levels in culture media of biologically old and young astrocytes 
Table shows Gene ID, mean MMP secretion in young (Y) and old (O) astrocytes (N=6) in arbitrary 
units, standard deviation, log-base 2 of fold change. T values and P values. Statistically significant (P 
<0.05) changes are denoted by * and row is shown in bold typeface, those approaching but not 
meeting statistical significance are shown in green. 
Gene  Mean Y SD  Mean O  SD Log2Fold 
Change 
T  p 
MMP-1 158.7 85.2 150.8 98.1 -0.07 -0.12 0.909 
MMP-2 29.8 24.1 11.63 15.99 -1.36 -1.26 0.264 
MMP-3 75.9 14.98 128.3 30.8 0.76 3.06 0.038* 
MMP-8 0.249 0.498 0 0   - - 
MMP-9 31.22 14.17 50.5 38.8 0.69 0.93 0.419 
MMP-10 6.28 6.29 18.57 5.15 1.56 3.02 0.029* 
MMP-13 58.9 21.4 11.63 18.62 -2.34 2.37 0.064 
TIMP-1 689.7 118 1074 291 0.64 2.45 0.091 
TIMP-2 4723 382 8403 1012 0.83 6.81 0.006* 
TIMP-4 156.7 38.8 203.6 163.7 0.38 1.79 0.133 
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Figure 3.3 Matrix Metalloproteinase Content 
MMP content in young vs old primary astrocytes (N=6). The light grey bar of each MMP represents 
the secreted MMP levels from young cells, and the dark grey bar of each colour represents the 
secreted MMP content from old cells. Statistically significant occurrences are marked with *. 
* = p < 0.05, ** = p < 0.005. 
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3.1.2 Changes in splicing factor expression and patterns of alternative splicing in senescent 
astrocytes 
We have previously demonstrated changes in splicing factor expression in senescent primary human 
cells of different lineages (33, 34, 37, 39). Similar changes were also apparent in senescent astrocytes, 
where 10/20 of the splicing factors tested demonstrated lower expression in late passage cells 
compared with earlier passage cells (Table 3.3, Figure 3.4). Both HNRNP splicing inhibitors and Serine-
arginine (SR) rich splicing activator transcripts demonstrated dysregulation; 4/8 (50%) transcripts 
encoding splicing inhibitors, 3/8 splicing activator transcripts and 3/4 (75%) of core spliceosomal 
transcripts demonstrated changed expression in senescent astrocytes. Most genes selected for study 
were expressed in astrocytes; only AQP4M1, EAAT2A and EAAT2B were not. 8 of the remaining 13 
transcripts demonstrated changes to their splicing patterns (Table 3.4, Error! Reference source not 
found.). 
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Table 3.3 Comparison of splicing factor levels in senescent and non-senescent astrocytes 
Values given refer to the mean expression of each splicing factor in either early or late passage cells 
(N=6). Values in parentheses are the standard error of the mean. Splicing factors demonstrating 
significant differences in expression are given in bold italic typeface. 3 biological and 3 technical 
replicates per sample. 
 
Splicing Factor Early passage astrocytes 
 
Late passage astrocytes p-value 
AKAP17A 1.035 (0.090) 1.01 (0.044) 0.077 
HNRNPA0 1.024 (0.077) 0.65 (0.031) 0.005 
HNRNPA1 1.236 (0.340) 1.863 (0.416) 0.449 
HNRNPA2B1 1.343 (0.353) 0.6 (0.108) 0.257 
HNRNPD 1.094 (0.180) 0.646 (0.048) 0.03 
HNRNPH3 1.071 (0.130) 0.743 (0.037) 0.003 
HNRNPK 1.153 (0.176) 1.37 (0.209) 0.551 
HNRNPM 1.021 (0.068) 0.66 (0.067) 0.012 
HNRNPUL2 1.074 (0.148) 0.784 (0.106) 0.089 
IMP3 1.088 (0.160) 0.62 (0.11) 0.035 
LSM14A 1.042 (0.113) 0.315 (0.047) 0.005 
LSM2 1.377 (0.426) 0.369 (0.045) 0.065 
PNISR 1.041 (0.098) 0.777 (0.030) 0.005 
SF3B1 1.018 (0.070) 0.716 (0.030) 0.018 
SRSF1 1.06 (0.140) 0.885 (0.038) 0.065 
SRSF2 1.038 (0.095) 1.017 (0.045) 0.121 
SRSF3 1.077 (0.175) 0.697 (0.032) 0.095 
SRSF6 1.07 (0.126) 0.762 (0.104) 0.098 
TRA2B 1.022 (0.081) 0.757 (0.057) 0.031* 
SRSF7 1.119 (0.198) 0.51 (0.063) 0.015* 
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Table 3.4 Comparison of alternative isoforms of selected brain or senescence genes in senescent and non-
senescent astrocytes 
Values given refer to the mean expression of each splicing factor in either early or late passage cells 
(N=6). Values in parentheses are the standard error of the mean. Transcripts demonstrating significant 
differences in expression as measured by t test are given in bold italic typeface, with p-values in right 
hand column. 3 biological and 3 technical replicates per sample. 
Transcript 
 
Early passage astrocytes 
 
Late passage astrocytes p-value 
GFAP(A) 0.809(0.208) 0.062(0.013) 0.0021** 
SKLOTHO 1.155(0.209) 0.498(0.275) 0.131 
MKLOTHO 1.059(0.122) 0.381(0.012) 0.005** 
AQPM23 1.252(0.459) 1.067(0.434) 0.784 
TAU3 1.044(0.114) 0.603(0.043) 0.023** 
TAU4 1.23(0.674) 1.542(0.196) 0.679 
PSEN2 1.009(0.12) 1.921(0.158) 0.01* 
CDKN2A-p14ARF 1.043(0.044) 0.532(0.048) 0.001*** 
CDKN2A-p16Ink4A 1.061(0.076) 2.133(0.127) 0.002** 
p21a 1.079(0.085) 1.666(0.087) 0.009* 
p21b 1.016(0.095) 2.041(0.077) 0.001*** 
TP53 0.974(0.052) 1.038(0.082) 0.541 
ATM 0.926(0.097) 0.612(0.069) 0.057 
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Figure 3.4 Heat map showing changes in splicing factor transcription between early and late passage 
astrocytes  (N=6) 
Non-statistically significant findings are blacked out. HNRNPA0, HNRNPD, HNRNPH3, HNRNPM, 
IMP3, LSM14A, PSISR, SF3B1, TRA2B, SRSF7, all displayed statistically significant changes in 
expression. Notably, most were downregulated, in line with current understanding suggesting that 
splicing factor expression decreases with age.  
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Heat map showing changes in isoform transcription between early and late passage astrocytes (N=6). 
Non-statistically significant findings are blacked out. Significant changes in isoform balance were 
observed in 8/13 mRNA species. Half of the transcripts experiencing significant changes were down 
regulated: GFAP(A), mKlotho, TAU3 (all related to astrocyte function) and P14 (cell cycle). We saw 
significant upregulation of 3 tumour-suppressive genes: P16, P21a and P21b, alongside PSEN2. GFAPa 
mKlotho, Tau3 and P14 had decreased expression.  
 
 
3.1.3 Association of senescence-related transcripts with cognitive decline in a longitudinal human 
population 
We next assessed whether any of the transcripts demonstrating senescence-related changes in aged 
primary human astrocytes were associated with cognitive decline as assessed by change in MMSE 
score between FU3 and FU4, in peripheral blood mRNA from individuals in the InCHIANTI study of 
aging. Of the 8 transcripts demonstrating associations with senescence in late passage astrocytes, 
Figure 3.5 Isoform expression in young vs old astrocytes (N=6). 
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TAU3, GFAP, mKLOTHO CDKN2A(p14ARF), CDKN2A(p16INK4A), CDKN1A(p21a), CDKN1A(p21b) and 
PSEN2 were also expressed in peripheral blood, and suitable for ongoing analysis. CDKN2A (p14ARF), 
and TAU3 were positively associated with mild cognitive decline (CDKN2A (p14ARF) beta coefficient 
0.122, 95% CI 0.01 to 0.24; p = 0.04, TAU3 beta coefficient 0.170, 95% CI 0.042 to 0.297; p = 0.01) 
whereas GFAPα was negatively associated with mild cognitive decline (beta coefficient -0.196 (95% CI 
-0.36 to 0.032; p = 0.02; figure 6; table 8). Interestingly the only association we found with severe 
cognitive decline was a negative association with TAU3 (beta coefficient -0.286, 95% CI -0.56 to 0.04; 
p = 0.04. GFAP and TAU3 demonstrated significant differences in level of isoform expression 
between mild and severe cognitive decline (Figure 3.6) (Table 3.5). 
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Table 3.5 Association between blood-based isoform production, induced by alternative splicing and cognitive decline in participants from the InCHIANTI population 
study of Aging 
The table gives the beta coefficients, 95% confidence intervals (95% CI) and p-values for the association between candidate transcript expression and 
cognitive decline as assessed by change in MMSE for 197 individuals in a 3-7 year period. Mild cognitive decline is categorised as a decline of between 2 and 
8 points in MMSE between FU3 and FU4, whereas severe cognitive decline is characterised as a decline of between 9 and 22 points. Transcripts 
demonstrating significant differences in expression are given in bold italic typeface. 
 
Mild cognitive decline (2 – 8 point decline in MMSE) Severe cognitive decline (9 – 22 point decline in MMSE) Difference between mild and severe decline in MMSE 
Isoform Beta 95% CI p-value Isoform Beta 95% CI p-value Isoform Beta 95% CI p-value 
GFAPα -0.196 -0.36 to 0.03 0.02 GFAPα 0.129 -0.23 to 0.49 0.48 GFAPα 0.363 0.08 to 0.65 0.01 
mKLOTHO -0.032 -0.16 to 0.09 0.61 mKLOTHO 0.070 -0.20 to 0.34 0.61 mKLOTHO 0.093 -0.18 to 0.37 0.50 
p14 0.122 0.01 to 0.24 0.04 p14 0.209 -0.04 to 0.46 0.10 p14 0.069 -0.18 to 0.32 0.59 
P16 -0.097 -0.29 to 0.09 0.31 P16 -0.095 -0.51 to 0.32 0.65 P16 -0.029 -0.45 to 0.40 0.89 
P21b -0.015 -0.11 to 0.08 0.74 P21b -0.085 -0.29 to 0.12 0.40 P21b -0.030 -0.22 to 0.16 0.75 
PSEN2 -0.075 -0.23 to 0.08 0.33 PSEN2 -0.215 -0.55 to 0.12 0.20 PSEN2 -0.133 -0.47 to 0.20 0.43 
TAU3 0.170 0.04 to 0.30 0.01 TAU3 -0.286 -0.56 to -0.01 0.04 TAU3 -0.460 -0.75 to -0.17 <0.01 
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Figure 3.6 Forrest Plot of association with cognitive decline of specific Isoforms in the InCHIANTI study of 
Aging 
The graph indicates the associations between peripheral blood expression of alternatively expressed 
transcripts of genes with known links with neurodegenerative disease or cellular senescence and 
mild or severe cognitive decline is given in this figure. Mild decline is denoted by open circles, severe 
decline is denoted by closed circles. * = p < 0.05. The null association point is given by the dotted 
line. Beta coefficients of association are given on the X axis and transcript identity are given on the Y 
axis. Data are from 197 participants classified as either mild cognitive decline (a reduction of 2-8 
points in MMSE performance over a 3-7 year period) or severe decline (a reduction of 9-22 points in 
MMSE performance over the same period). 
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The accumulation of senescent cells due to repeated cell stresses is thought to be a major contributor 
to ageing and age-related disease. The ablation of senescent cells can bring about improvements in 
multiple age-related phenotypes in animal models (15, 17). Furthermore, correlations exist between 
circulating levels of senescence markers such as p16INK4a and HMGB2 and functional status in humans 
(207).  Suppression of senescent cell characteristics such as SASP using the flavonoid apigenin has also 
been demonstrated to reduce aggressive behaviour in breast cancer cells, providing further evidence 
that reduction of senescent cell load may bring benefits for age-related diseases (208).  To date, there 
have been a limited recorded trials of senolytics in humans (209, 210), although each with positive 
results. In September 2019, it was finally demonstrated that senolytics could clear senescent cells from 
the bodies of humans (211).  
Whilst the evolution of cellular senescence is understood to have emerged in part because of the 
tumour suppressive properties of the cell state, the senescence associated secretory phenotype has 
deleterious properties and the inflammatory paracrine effect can drive tumorigenesis in surrounding 
tissues. Therefore, whilst the individual cell may use the senescence pathway to escape neoplasm 
formation, the relief is only a temporary one. Senescent cell development triggers a chain reaction, 
propagating dysfunction through tissues by inflammation. This tumour suppressive “side-effect” 
appears to be a typical example of evolution precipitating antagonistic pleiotropic effects, commonly 
associated with ageing (212).  
Based on evidence linking senescence to RNA processing, we hypothesised that senescent astrocytes 
would display differential expression of splicing regulatory factors and altered patterns of alternative 
splicing in vitro. We also suggested that due to the systemic nature of ageing, or the blood brain barrier 
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degradation over time, some of these isoform changes may be detectable in peripheral blood and 
show statistical associations with cognitive phenotypes in human populations.  
Initially were able to show that replication competent, primary human astrocytes in culture do indeed 
reach a senescent state, simply through continued passage, and we generated evidence for a direct 
link between this and the reduction in splicing faction expression, demonstrably critical to normal 
transcriptional regulation and response to environmental stress.  We also have found functional 
evidence that the expression changes of splicing factors in a highly senescent cell population appear 
to be able to drive imbalances in isoform species known to be highly important in astrocyte function. 
What is not yet clear, is if senescence drives dysregulation, if dysregulation drives senescence, or if in 
fact they are both ‘symptoms’ of some other event. 
As such, age-related dysregulation of alternative splicing may contribute to or be a result of the 
accumulation of senescent cells during ageing. It would be of importance to ascertain if re-regulation 
of splicing in this cell line using small molecule effectors of splicing is possible, and if this can then 
modify the senescence state. Restoration of splicing factor expression can reverse cellular senescence 
and bring about rejuvenation of multiple other cell types in culture.  
A look at the in-vitro results of isoform expression demonstrates results congruent with the 
senescence hypothesis, and with evidence available in existing literature regarding the expression of 
tumour suppressors P53, P16, and P21a. Specifically, we observed a robust increase in the expression 
of P16, P21a and P53 isoforms overall in an aged cell population as seen elsewhere (213).  Even more 
encouraging was the observation that P14 expression, which produces a protein known to be 
associated with cell cycle arrest and premature senescence was positively associated with cognitive 
decline in our population study, providing potential biomarker for the pathology or even perhaps 
therapeutic targets.  
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We demonstrated that 50% of splicing factor transcripts we measured demonstrated dysregulated 
expression in senescent astrocytes, and splicing changes were evident for almost half of the 
alternatively spliced genes in an a priori panel of candidate genes. The changes in astrocyte splicing 
factor and isoform expression we have identified here, likely do not act directly on the transcriptome 
observable in whole blood, but rather reflect related cognition-associated changes to systemic splicing 
factor expression; changes which are also observable in blood, as we have recently described (35) 
 8/13 candidate isoforms demonstrated splicing alterations in senescent cells and were also expressed 
in human peripheral blood. Of these, 3 (TAU3, GFAPand CDKN2A (p14ARF) were associated with mild 
cognitive decline in ageing humans. The TAU3 isoform was also associated with severe cognitive 
decline, but in an opposing direction. Our data are consistent with a model whereby age-related 
splicing factor changes may lead to splicing patterns for genes with roles in brain function or 
senescence, which may influence the development of cognitive decline in the human population. The 
links between splicing factor changes and isoform changes are impossible to predict from global 
measures. Each individual splice site in each gene is regulated by a unique and specific combination 
of activators and inhibitors which determine its usage or not, which makes prediction impossible from 
levels alone. What our data do indicate is that senescent astrocytes have disrupted expression of many 
splicing factors, which would be predicted to alter the splicing patterns. We have demonstrated that 
this holds true for several genes important in senescence or in astrocyte function. 
The presence of senescent cells has been suggested to contribute to shortened overall lifespan (16), 
and clearance of such cells was able to bring about a delay in the appearance of ageing phenotypes in 
ageing mice (17). Other groups have reported increased lifespan, rejuvenation of ageing phenotypes 
such as thinning fur and improved kidney function in old mice that have undergone targeted removal 
of senescent cells (214). Ablation of senescent glial cells has been demonstrated to lead to a reduction 
of Tau-dependent pathology and improve cognitive function in mice (23). Accordingly, we observe the 
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generation of a strong SASP in astrocytes that have undergone replicative senescence, which may be 
contributory to the inflammatory increases evident in the pathophysiology of neurodegeneration. The 
SASP profile exhibited by the primary human astrocytes does not match that profile seen in other cell 
lines from our previous work (34, 37, 39), however cell type specificity in SASP has previously been 
described (215). The reasons behind these variations are unclear, but may reflect histologically 
discrete programmes, dysregulation patterns specific to existing transcriptomic profiles, or simply 
arbitrary patterns of cytokine production which represent the stochastic molecular dysregulation 
which is occurring. 
Unpicking the specific components of the SASP is no easy task. Investigation into existing literature 
does demonstrate astrocyte specific IL-8 secretion during times of stress such as acidosis (216). IL-8 
has neuroprotective and neurotrophic effects and is an angiogenesis promotor. It drives production 
of brain derived neurotrophic factor and seems to prevent amyloid beta induced apoptosis in 
Alzheimer’s. IL-8 was found to be much higher concentrations in the CSF of individuals with mild 
cognitive impairment as opposed to those with Alzheimer’s (217). 
Our observations, together with the marked changes in splicing factor expression are suggestive that 
the intersection between disrupted regulation of splicing, cellular senescence and its associated 
inflammatory phenotype in astrocytes may contribute to astrocyte dysfunction and have some 
bearing on eventual cognitive decline. Similar changes may also be occurring in other important 
proliferative brain cell types such as microglia.  
Similarly, the altered expression of alternatively expressed transcripts in blood may be reflective of 
changes that we demonstrate here also occur in astrocytes. We identified positive associations 
between CDKN2A (p14ARF), and TAU3 expression in peripheral blood and mild cognitive decline, and a 
negative correlation between GFAP expression and mild cognitive decline. The associations between 
Alternative splicing and age-related neurodegeneration – Jed Lye 
Page 69 of 86 
 
GFAPΑ and CDKN2A (p14ARF) were not apparent in severe cognitive decline, although this may reflect 
low power imposed by the inherent variability of human biological samples, since p14 expression in 
severe decline is trending in the same direction.  
 The association of TAU3 expression with severe cognitive decline was still evident, but was negatively, 
rather than positively correlated. GFAP expression also demonstrates opposing direction of effect 
between mild and severe decline. This may represent differences in cell subtype populations or altered 
cell characteristics between disease states. GFAP, which along with other intermediate filaments 
forms the cytoskeleton is important for signal transduction and structural properties (218). GFAP is 
highly expressed during key developmental stages during gestation, and has also been observed to 
have elevated expression levels in brain damage and a range of neurological diseases (218). Some 
studies have reported no change in whole blood GFAP protein levels, and hypothesised that without 
rapid astroglial destruction, GFAPα levels may not climb to a detectable level and thus may not be a 
good indicator of neurological pathology (219). Such studies however may not detect changes at the 
level of isoforms, if appropriate antibodies capable of specifically identifying individual splice variants 
are not used.  
Increased levels of CDKN2A (p14ARF) may be reflective of an increased load of senescent cells, and is 
one of two proteins produced by alternate reading frame of the CDKN2A locus (220). p14ARF inhibits 
the activity of MDM2, a protein which sequesters the p53 protein (221). Once p53 stabilises and 
accumulates it can trigger DNA repair or the apoptosis program of cell death (222). The consequences 
of increased p14ARF levels are complex and in places conflicted. It has been demonstrated to induce 
either cellular senescence or apoptosis in a p53 dependant manner (220). There have also been some 
reports that although CDKN2A (p14ARF) transcripts are upregulated in senescent cells, TP53 and MDM2 
levels can remain unchanged (221). Ectopic expression of p14ARF is capable of inducing senescence but 
overexpression must be maintained to commit cells to a senescent state (223). 
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 TAU3 transcript expression in the blood was observed to be correlated positively with mild cognitive 
decline, but interestingly, negatively correlated with severe cognitive decline. Microtubule associated 
protein Tau (MAPT) is an alternatively spliced regulator of microtubule dynamics – which is essential 
for cellular functions from structure to transport (224). An ever growing body of research in human 
and animal models of tauopathies is demonstrating that the delicately balanced 2:1 3R/4R TAU ratio 
(225), which is achieved through alternative splicing of exon 10, is imperative for maintaining healthy 
function in cells in the brain, and shifts to disrupt this balance in either direction can be catastrophic 
(225-228). A number of neurodegenerative diseases, including Alzheimer’s and frontotemporal 
dementia (FTD), have had tau isoform balance (specifically 3R and 4R isoforms) implicated in their 
pathophysiology (224, 229, 230). These include those examples with premature cognitive decline 
(231). The precise mechanisms by which TAU isoforms specifically contribute to each neurological 
pathology are still being investigated. The directionality of association between TAU3 transcript levels 
and mild and severe decline are consistent with existing literature suggesting imbalances in 3R/4R 
isoform ratios, rather than absolute isoform levels per se, are identified in cases of dementia and 
examples of neurodegenerative disease (225, 232). 
Our finding of dysregulated splicing factor expression in human primary astrocytes is novel, and 
consistent with reports from senescent cells of other tissue types (33, 34, 37, 39). Our study benefits 
from a systematic cells-to-populations approach including primary human cell lines and an exquisitely 
characterised longitudinal population study. Weaknesses of this study are the initial assessment in 
isolated astrocytes, which may not represent the holistic nature of the cytological and molecular 
mechanisms involved in cognitive decline and may not capture the extent of cross talk between other 
cell types in the human brain. It also needs to be recognised that the astrocytes used in this study 
derive from a single donor, and that differences reported here would benefit from confirmation in 
individuals of different genetic background.  Cell lines from a wider variety of donors may return more 
genes of interest, however these tissues are rare, and difficult to acquire. In addition, our a priori list 
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of genes do not include many other isoforms and genes involved in the process. Several of the isoforms 
selected for study are also not strictly specific for astrocytes. This is particularly true of the senescence 
genes tested, which reflect players in a more global mechanism. Our scope was narrowed by the need 
for these genes to be expressed in the blood, for assessment of association with living population. 
Further work may benefit from whole transcriptome sequencing and transcriptional profiling in 
several different cell types.  
Our data are consistent with a model by which accumulation of senescent astrocytes (and doubtless 
other important brain cell subtypes), their associated disrupted splicing patterns and the increased 
inflammatory microenvironment may contribute to premature cognitive decline. Inflammation and 
related cellular stresses are capable of activating cell signalling pathways and lead to further 
dysregulation of splicing factor expression (38), so it is possible that an auto-regulated feedback loop 
involving SASP-derived increases in inflammation, dysregulated splicing regulation and subsequent 
further increases in senescent cell load may occur as a result of positive feedback. The idea that some 
of the features of cognitive decline could therefore arise from dysregulated splicing of genes 
important in the support cells of the brain requires further exploration. This could be explored further 
by the selective manipulation of specific isoform levels, followed by assessment of effects on astrocyte 
cell kinetics or astrocyte function in cells and in systems. Our observations suggest that the role of 
splicing factor expression and dysregulated alternative splicing in cognitive decline may represent an 
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